Quantum BioPharma Enters Into Binding LOI With Allucent To Support Planned Phase 2 Clinical Trial Of Lucid-MS For Treatment Of Multiple Sclerosis

Quantum BioPharma Ltd. has entered into a binding Letter of Intent with Allucent to support a planned Phase 2 clinical trial of its treatment, Lucid-MS, for multiple sclerosis. This partnership marks a significant milestone in the company's clinical development pipeline, with the trial expected to evaluate the efficacy, safety, and tolerability of Lucid-MS. The Phase 2 trial is anticipated to begin in the second quarter of 2026, pending regulatory approvals and finalization of trial arrangements.